BNP Paribas Financial Markets
TRML

BNP Paribas Financial Markets’s Tourmaline Bio TRML Stock Holding History

BNP Paribas Financial Markets’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,841
Closed -$232K – 5960
2025
Q3 		$232K Buy
4,841
+2,738
+130% +$75.9K ﹤0.01% 3940
2025
Q2 		$33.6K Buy
2,103
+535
+34% +$8.67K ﹤0.01% 4395
2025
Q1 		$23.8K Sell
1,568
-1,803
-53% -$28.9K ﹤0.01% 4492
2024
Q4 		$68.4K Sell
3,371
-9,977
-75% -$251K ﹤0.01% 4312
2024
Q3 		$343K Sell
13,348
-1,132
-8% -$18.9K ﹤0.01% 3017
2024
Q2 		$186K Buy
14,480
+13,134
+976% +$211K ﹤0.01% 3123
2024
Q1 		$30.8K Buy
+1,346
New +$47.5K ﹤0.01% 3615
2022
Q4 		– Sell
-2,448
Closed -$64.4K – 4606
2022
Q3 		$64.4K Buy
+2,448
New +$89.2K ﹤0.01% 3925

BNP Paribas Financial Markets's TRML Position: Q4 2025 in Review

BNP Paribas Financial Markets sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 4,841 shares — an estimated $232K sold.

BNP Paribas Financial Markets first reported a position in TRML in Q3 2022 and held it in 8 quarters. The position peaked at $343K in Q3 2024. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.

  • BNP Paribas Financial Markets reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 4,841 Tourmaline Bio shares in Q4 2025, an estimated $232K.
  • BNP Paribas Financial Markets first reported a position in Tourmaline Bio in Q3 2022 and held it in 8 quarters.
  • BNP Paribas Financial Markets's Tourmaline Bio position peaked at $343K in Q3 2024.
  • 0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.

Based on BNP Paribas Financial Markets's 13F filing for Q4 2025, filed 10 Feb 2026.